Global Acute Intermittent Porphyria

Acute Intermittent Porphyria Comprehensive Study by Treatment (Gonadotropin-Releasing Hormone Analogues, Prophylactic Hematin Infusions, Others), Diagnosis (Blood Test, Urine Test, DNA Test, Serum Test), End User (Hospitals, Clinics, Research Centers, Others) Players and Region - Global Market Outlook to 2028

Acute Intermittent Porphyria Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Acute Intermittent Porphyria Market Overview:
Acute intermittent porphyria is a hereditary metabolic disorder. It affects the production of heme, which is the prosthetic group of hemoglobin binding to oxygen. It is caused due to low enzyme porphobilinogen deaminase. The main reasons for acute intermittent porphyria are insomnia, anorexia, and change in coloration of urine, myalgia, and retention of urine. Porphyria is caused by the development of chemicals in the body that creates a substance called porphyrin. Acute intermittent porphyria is a hereditary metabolic disorder and is one of the eight kinds of porphyria. If any of the parents is suffering from this disorder, the child has a 50 % chance of inheriting any of the eight porphyria disorders.

AttributesDetails
Study Period2018-2028
Base Year2022
Forecast Period2023-2028
Historical Period2018-2022
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Influencing Trend:
Increase in the Availability of Funds

Market Growth Drivers:
Increasing Prevalence of Rare Diseases, Developing Interest for Better Treatment and Expanding Growth in Biotechnology and Pharmaceutical Ventures for Research and Development

Challenges:
Fewer Reimbursement Facilities in Emerging Economies

Restraints:
High Treatment Cost Associated with Advancing Health Care Technologies

Opportunities:
Increasing Government Support for Research and Advancement and Rapidly Developing Innovation

Competitive Landscape:
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Boston Scientific Corporation (United States), Koninklijke Philips N.V. (Netherlands), Siemens AG(Germany), C.R. Bard Inc. (United States), 3M (United States), Danaher Corporation (United States), F. Hoffmann-La Roche Ltd (Switzerland), Bio-Rad Laboratories, Inc. (United States), ARKRAY, Inc. (Japan), Sysmex Corporation (Japan), ACON Laboratories, Inc. (United States) and Sonova (Switzerland). Analyst at AMA Research see United States Players to retain maximum share of Global Acute Intermittent Porphyria market by 2028. Considering Market by Treatment, the sub-segment i.e. Gonadotropin-Releasing Hormone Analogues will boost the Acute Intermittent Porphyria market. Considering Market by Diagnosis, the sub-segment i.e. Blood Test will boost the Acute Intermittent Porphyria market. Considering Market by End User, the sub-segment i.e. Hospitals will boost the Acute Intermittent Porphyria market.

Latest Market Insights:
In November 2022, Boston Scientific Acquired Apollo Endosurgery, Inc. Apollo Endosurgery is a medical device company that specializes in minimally invasive surgical solutions for the treatment of obesity and other gastrointestinal conditions. Through this acquisition, Boston Scientific aims to enhance its portfolio of endoscopy and minimally invasive surgical solutions and expand its presence in the growing field of bariatric and gastrointestinal procedures. The agreement reflects Boston Scientific's commitment to delivering innovative and comprehensive healthcare solutions to improve patient outcomes.

What Can be Explored with the Acute Intermittent Porphyria Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Acute Intermittent Porphyria Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Acute Intermittent Porphyria
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Acute Intermittent Porphyria market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Acute Intermittent Porphyria market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Acute Intermittent Porphyria Drugs Providers, Research Organizations and Consulting Companies, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Treatment
  • Gonadotropin-Releasing Hormone Analogues
  • Prophylactic Hematin Infusions
  • Others

By Diagnosis
  • Blood Test
  • Urine Test
  • DNA Test
  • Serum Test

By End User
  • Hospitals
  • Clinics
  • Research Centers
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Rare Diseases
      • 3.2.2. Developing Interest for Better Treatment
      • 3.2.3. Expanding Growth in Biotechnology and Pharmaceutical Ventures for Research and Development
    • 3.3. Market Challenges
      • 3.3.1. Fewer Reimbursement Facilities in Emerging Economies
    • 3.4. Market Trends
      • 3.4.1. Increase in the Availability of Funds
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Acute Intermittent Porphyria, by Treatment, Diagnosis, End User and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Acute Intermittent Porphyria (Value)
      • 5.2.1. Global Acute Intermittent Porphyria by: Treatment (Value)
        • 5.2.1.1. Gonadotropin-Releasing Hormone Analogues
        • 5.2.1.2. Prophylactic Hematin Infusions
        • 5.2.1.3. Others
      • 5.2.2. Global Acute Intermittent Porphyria by: Diagnosis (Value)
        • 5.2.2.1. Blood Test
        • 5.2.2.2. Urine Test
        • 5.2.2.3. DNA Test
        • 5.2.2.4. Serum Test
      • 5.2.3. Global Acute Intermittent Porphyria by: End User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clinics
        • 5.2.3.3. Research Centers
        • 5.2.3.4. Others
      • 5.2.4. Global Acute Intermittent Porphyria Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Acute Intermittent Porphyria: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Boston Scientific Corporation (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Koninklijke Philips N.V. (Netherlands)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Siemens AG(Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. C.R. Bard Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. 3M (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Danaher Corporation (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bio-Rad Laboratories, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. ARKRAY, Inc. (Japan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Sysmex Corporation (Japan)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. ACON Laboratories, Inc. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Sonova (Switzerland)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Acute Intermittent Porphyria Sale, by Treatment, Diagnosis, End User and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Acute Intermittent Porphyria (Value)
      • 7.2.1. Global Acute Intermittent Porphyria by: Treatment (Value)
        • 7.2.1.1. Gonadotropin-Releasing Hormone Analogues
        • 7.2.1.2. Prophylactic Hematin Infusions
        • 7.2.1.3. Others
      • 7.2.2. Global Acute Intermittent Porphyria by: Diagnosis (Value)
        • 7.2.2.1. Blood Test
        • 7.2.2.2. Urine Test
        • 7.2.2.3. DNA Test
        • 7.2.2.4. Serum Test
      • 7.2.3. Global Acute Intermittent Porphyria by: End User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clinics
        • 7.2.3.3. Research Centers
        • 7.2.3.4. Others
      • 7.2.4. Global Acute Intermittent Porphyria Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Acute Intermittent Porphyria: by Treatment(USD Million)
  • Table 2. Acute Intermittent Porphyria Gonadotropin-Releasing Hormone Analogues , by Region USD Million (2017-2022)
  • Table 3. Acute Intermittent Porphyria Prophylactic Hematin Infusions , by Region USD Million (2017-2022)
  • Table 4. Acute Intermittent Porphyria Others , by Region USD Million (2017-2022)
  • Table 5. Acute Intermittent Porphyria: by Diagnosis(USD Million)
  • Table 6. Acute Intermittent Porphyria Blood Test , by Region USD Million (2017-2022)
  • Table 7. Acute Intermittent Porphyria Urine Test , by Region USD Million (2017-2022)
  • Table 8. Acute Intermittent Porphyria DNA Test , by Region USD Million (2017-2022)
  • Table 9. Acute Intermittent Porphyria Serum Test , by Region USD Million (2017-2022)
  • Table 10. Acute Intermittent Porphyria: by End User(USD Million)
  • Table 11. Acute Intermittent Porphyria Hospitals , by Region USD Million (2017-2022)
  • Table 12. Acute Intermittent Porphyria Clinics , by Region USD Million (2017-2022)
  • Table 13. Acute Intermittent Porphyria Research Centers , by Region USD Million (2017-2022)
  • Table 14. Acute Intermittent Porphyria Others , by Region USD Million (2017-2022)
  • Table 15. South America Acute Intermittent Porphyria, by Country USD Million (2017-2022)
  • Table 16. South America Acute Intermittent Porphyria, by Treatment USD Million (2017-2022)
  • Table 17. South America Acute Intermittent Porphyria, by Diagnosis USD Million (2017-2022)
  • Table 18. South America Acute Intermittent Porphyria, by End User USD Million (2017-2022)
  • Table 19. Brazil Acute Intermittent Porphyria, by Treatment USD Million (2017-2022)
  • Table 20. Brazil Acute Intermittent Porphyria, by Diagnosis USD Million (2017-2022)
  • Table 21. Brazil Acute Intermittent Porphyria, by End User USD Million (2017-2022)
  • Table 22. Argentina Acute Intermittent Porphyria, by Treatment USD Million (2017-2022)
  • Table 23. Argentina Acute Intermittent Porphyria, by Diagnosis USD Million (2017-2022)
  • Table 24. Argentina Acute Intermittent Porphyria, by End User USD Million (2017-2022)
  • Table 25. Rest of South America Acute Intermittent Porphyria, by Treatment USD Million (2017-2022)
  • Table 26. Rest of South America Acute Intermittent Porphyria, by Diagnosis USD Million (2017-2022)
  • Table 27. Rest of South America Acute Intermittent Porphyria, by End User USD Million (2017-2022)
  • Table 28. Asia Pacific Acute Intermittent Porphyria, by Country USD Million (2017-2022)
  • Table 29. Asia Pacific Acute Intermittent Porphyria, by Treatment USD Million (2017-2022)
  • Table 30. Asia Pacific Acute Intermittent Porphyria, by Diagnosis USD Million (2017-2022)
  • Table 31. Asia Pacific Acute Intermittent Porphyria, by End User USD Million (2017-2022)
  • Table 32. China Acute Intermittent Porphyria, by Treatment USD Million (2017-2022)
  • Table 33. China Acute Intermittent Porphyria, by Diagnosis USD Million (2017-2022)
  • Table 34. China Acute Intermittent Porphyria, by End User USD Million (2017-2022)
  • Table 35. Japan Acute Intermittent Porphyria, by Treatment USD Million (2017-2022)
  • Table 36. Japan Acute Intermittent Porphyria, by Diagnosis USD Million (2017-2022)
  • Table 37. Japan Acute Intermittent Porphyria, by End User USD Million (2017-2022)
  • Table 38. India Acute Intermittent Porphyria, by Treatment USD Million (2017-2022)
  • Table 39. India Acute Intermittent Porphyria, by Diagnosis USD Million (2017-2022)
  • Table 40. India Acute Intermittent Porphyria, by End User USD Million (2017-2022)
  • Table 41. South Korea Acute Intermittent Porphyria, by Treatment USD Million (2017-2022)
  • Table 42. South Korea Acute Intermittent Porphyria, by Diagnosis USD Million (2017-2022)
  • Table 43. South Korea Acute Intermittent Porphyria, by End User USD Million (2017-2022)
  • Table 44. Taiwan Acute Intermittent Porphyria, by Treatment USD Million (2017-2022)
  • Table 45. Taiwan Acute Intermittent Porphyria, by Diagnosis USD Million (2017-2022)
  • Table 46. Taiwan Acute Intermittent Porphyria, by End User USD Million (2017-2022)
  • Table 47. Australia Acute Intermittent Porphyria, by Treatment USD Million (2017-2022)
  • Table 48. Australia Acute Intermittent Porphyria, by Diagnosis USD Million (2017-2022)
  • Table 49. Australia Acute Intermittent Porphyria, by End User USD Million (2017-2022)
  • Table 50. Rest of Asia-Pacific Acute Intermittent Porphyria, by Treatment USD Million (2017-2022)
  • Table 51. Rest of Asia-Pacific Acute Intermittent Porphyria, by Diagnosis USD Million (2017-2022)
  • Table 52. Rest of Asia-Pacific Acute Intermittent Porphyria, by End User USD Million (2017-2022)
  • Table 53. Europe Acute Intermittent Porphyria, by Country USD Million (2017-2022)
  • Table 54. Europe Acute Intermittent Porphyria, by Treatment USD Million (2017-2022)
  • Table 55. Europe Acute Intermittent Porphyria, by Diagnosis USD Million (2017-2022)
  • Table 56. Europe Acute Intermittent Porphyria, by End User USD Million (2017-2022)
  • Table 57. Germany Acute Intermittent Porphyria, by Treatment USD Million (2017-2022)
  • Table 58. Germany Acute Intermittent Porphyria, by Diagnosis USD Million (2017-2022)
  • Table 59. Germany Acute Intermittent Porphyria, by End User USD Million (2017-2022)
  • Table 60. France Acute Intermittent Porphyria, by Treatment USD Million (2017-2022)
  • Table 61. France Acute Intermittent Porphyria, by Diagnosis USD Million (2017-2022)
  • Table 62. France Acute Intermittent Porphyria, by End User USD Million (2017-2022)
  • Table 63. Italy Acute Intermittent Porphyria, by Treatment USD Million (2017-2022)
  • Table 64. Italy Acute Intermittent Porphyria, by Diagnosis USD Million (2017-2022)
  • Table 65. Italy Acute Intermittent Porphyria, by End User USD Million (2017-2022)
  • Table 66. United Kingdom Acute Intermittent Porphyria, by Treatment USD Million (2017-2022)
  • Table 67. United Kingdom Acute Intermittent Porphyria, by Diagnosis USD Million (2017-2022)
  • Table 68. United Kingdom Acute Intermittent Porphyria, by End User USD Million (2017-2022)
  • Table 69. Netherlands Acute Intermittent Porphyria, by Treatment USD Million (2017-2022)
  • Table 70. Netherlands Acute Intermittent Porphyria, by Diagnosis USD Million (2017-2022)
  • Table 71. Netherlands Acute Intermittent Porphyria, by End User USD Million (2017-2022)
  • Table 72. Rest of Europe Acute Intermittent Porphyria, by Treatment USD Million (2017-2022)
  • Table 73. Rest of Europe Acute Intermittent Porphyria, by Diagnosis USD Million (2017-2022)
  • Table 74. Rest of Europe Acute Intermittent Porphyria, by End User USD Million (2017-2022)
  • Table 75. MEA Acute Intermittent Porphyria, by Country USD Million (2017-2022)
  • Table 76. MEA Acute Intermittent Porphyria, by Treatment USD Million (2017-2022)
  • Table 77. MEA Acute Intermittent Porphyria, by Diagnosis USD Million (2017-2022)
  • Table 78. MEA Acute Intermittent Porphyria, by End User USD Million (2017-2022)
  • Table 79. Middle East Acute Intermittent Porphyria, by Treatment USD Million (2017-2022)
  • Table 80. Middle East Acute Intermittent Porphyria, by Diagnosis USD Million (2017-2022)
  • Table 81. Middle East Acute Intermittent Porphyria, by End User USD Million (2017-2022)
  • Table 82. Africa Acute Intermittent Porphyria, by Treatment USD Million (2017-2022)
  • Table 83. Africa Acute Intermittent Porphyria, by Diagnosis USD Million (2017-2022)
  • Table 84. Africa Acute Intermittent Porphyria, by End User USD Million (2017-2022)
  • Table 85. North America Acute Intermittent Porphyria, by Country USD Million (2017-2022)
  • Table 86. North America Acute Intermittent Porphyria, by Treatment USD Million (2017-2022)
  • Table 87. North America Acute Intermittent Porphyria, by Diagnosis USD Million (2017-2022)
  • Table 88. North America Acute Intermittent Porphyria, by End User USD Million (2017-2022)
  • Table 89. United States Acute Intermittent Porphyria, by Treatment USD Million (2017-2022)
  • Table 90. United States Acute Intermittent Porphyria, by Diagnosis USD Million (2017-2022)
  • Table 91. United States Acute Intermittent Porphyria, by End User USD Million (2017-2022)
  • Table 92. Canada Acute Intermittent Porphyria, by Treatment USD Million (2017-2022)
  • Table 93. Canada Acute Intermittent Porphyria, by Diagnosis USD Million (2017-2022)
  • Table 94. Canada Acute Intermittent Porphyria, by End User USD Million (2017-2022)
  • Table 95. Mexico Acute Intermittent Porphyria, by Treatment USD Million (2017-2022)
  • Table 96. Mexico Acute Intermittent Porphyria, by Diagnosis USD Million (2017-2022)
  • Table 97. Mexico Acute Intermittent Porphyria, by End User USD Million (2017-2022)
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Acute Intermittent Porphyria: by Treatment(USD Million)
  • Table 111. Acute Intermittent Porphyria Gonadotropin-Releasing Hormone Analogues , by Region USD Million (2023-2028)
  • Table 112. Acute Intermittent Porphyria Prophylactic Hematin Infusions , by Region USD Million (2023-2028)
  • Table 113. Acute Intermittent Porphyria Others , by Region USD Million (2023-2028)
  • Table 114. Acute Intermittent Porphyria: by Diagnosis(USD Million)
  • Table 115. Acute Intermittent Porphyria Blood Test , by Region USD Million (2023-2028)
  • Table 116. Acute Intermittent Porphyria Urine Test , by Region USD Million (2023-2028)
  • Table 117. Acute Intermittent Porphyria DNA Test , by Region USD Million (2023-2028)
  • Table 118. Acute Intermittent Porphyria Serum Test , by Region USD Million (2023-2028)
  • Table 119. Acute Intermittent Porphyria: by End User(USD Million)
  • Table 120. Acute Intermittent Porphyria Hospitals , by Region USD Million (2023-2028)
  • Table 121. Acute Intermittent Porphyria Clinics , by Region USD Million (2023-2028)
  • Table 122. Acute Intermittent Porphyria Research Centers , by Region USD Million (2023-2028)
  • Table 123. Acute Intermittent Porphyria Others , by Region USD Million (2023-2028)
  • Table 124. South America Acute Intermittent Porphyria, by Country USD Million (2023-2028)
  • Table 125. South America Acute Intermittent Porphyria, by Treatment USD Million (2023-2028)
  • Table 126. South America Acute Intermittent Porphyria, by Diagnosis USD Million (2023-2028)
  • Table 127. South America Acute Intermittent Porphyria, by End User USD Million (2023-2028)
  • Table 128. Brazil Acute Intermittent Porphyria, by Treatment USD Million (2023-2028)
  • Table 129. Brazil Acute Intermittent Porphyria, by Diagnosis USD Million (2023-2028)
  • Table 130. Brazil Acute Intermittent Porphyria, by End User USD Million (2023-2028)
  • Table 131. Argentina Acute Intermittent Porphyria, by Treatment USD Million (2023-2028)
  • Table 132. Argentina Acute Intermittent Porphyria, by Diagnosis USD Million (2023-2028)
  • Table 133. Argentina Acute Intermittent Porphyria, by End User USD Million (2023-2028)
  • Table 134. Rest of South America Acute Intermittent Porphyria, by Treatment USD Million (2023-2028)
  • Table 135. Rest of South America Acute Intermittent Porphyria, by Diagnosis USD Million (2023-2028)
  • Table 136. Rest of South America Acute Intermittent Porphyria, by End User USD Million (2023-2028)
  • Table 137. Asia Pacific Acute Intermittent Porphyria, by Country USD Million (2023-2028)
  • Table 138. Asia Pacific Acute Intermittent Porphyria, by Treatment USD Million (2023-2028)
  • Table 139. Asia Pacific Acute Intermittent Porphyria, by Diagnosis USD Million (2023-2028)
  • Table 140. Asia Pacific Acute Intermittent Porphyria, by End User USD Million (2023-2028)
  • Table 141. China Acute Intermittent Porphyria, by Treatment USD Million (2023-2028)
  • Table 142. China Acute Intermittent Porphyria, by Diagnosis USD Million (2023-2028)
  • Table 143. China Acute Intermittent Porphyria, by End User USD Million (2023-2028)
  • Table 144. Japan Acute Intermittent Porphyria, by Treatment USD Million (2023-2028)
  • Table 145. Japan Acute Intermittent Porphyria, by Diagnosis USD Million (2023-2028)
  • Table 146. Japan Acute Intermittent Porphyria, by End User USD Million (2023-2028)
  • Table 147. India Acute Intermittent Porphyria, by Treatment USD Million (2023-2028)
  • Table 148. India Acute Intermittent Porphyria, by Diagnosis USD Million (2023-2028)
  • Table 149. India Acute Intermittent Porphyria, by End User USD Million (2023-2028)
  • Table 150. South Korea Acute Intermittent Porphyria, by Treatment USD Million (2023-2028)
  • Table 151. South Korea Acute Intermittent Porphyria, by Diagnosis USD Million (2023-2028)
  • Table 152. South Korea Acute Intermittent Porphyria, by End User USD Million (2023-2028)
  • Table 153. Taiwan Acute Intermittent Porphyria, by Treatment USD Million (2023-2028)
  • Table 154. Taiwan Acute Intermittent Porphyria, by Diagnosis USD Million (2023-2028)
  • Table 155. Taiwan Acute Intermittent Porphyria, by End User USD Million (2023-2028)
  • Table 156. Australia Acute Intermittent Porphyria, by Treatment USD Million (2023-2028)
  • Table 157. Australia Acute Intermittent Porphyria, by Diagnosis USD Million (2023-2028)
  • Table 158. Australia Acute Intermittent Porphyria, by End User USD Million (2023-2028)
  • Table 159. Rest of Asia-Pacific Acute Intermittent Porphyria, by Treatment USD Million (2023-2028)
  • Table 160. Rest of Asia-Pacific Acute Intermittent Porphyria, by Diagnosis USD Million (2023-2028)
  • Table 161. Rest of Asia-Pacific Acute Intermittent Porphyria, by End User USD Million (2023-2028)
  • Table 162. Europe Acute Intermittent Porphyria, by Country USD Million (2023-2028)
  • Table 163. Europe Acute Intermittent Porphyria, by Treatment USD Million (2023-2028)
  • Table 164. Europe Acute Intermittent Porphyria, by Diagnosis USD Million (2023-2028)
  • Table 165. Europe Acute Intermittent Porphyria, by End User USD Million (2023-2028)
  • Table 166. Germany Acute Intermittent Porphyria, by Treatment USD Million (2023-2028)
  • Table 167. Germany Acute Intermittent Porphyria, by Diagnosis USD Million (2023-2028)
  • Table 168. Germany Acute Intermittent Porphyria, by End User USD Million (2023-2028)
  • Table 169. France Acute Intermittent Porphyria, by Treatment USD Million (2023-2028)
  • Table 170. France Acute Intermittent Porphyria, by Diagnosis USD Million (2023-2028)
  • Table 171. France Acute Intermittent Porphyria, by End User USD Million (2023-2028)
  • Table 172. Italy Acute Intermittent Porphyria, by Treatment USD Million (2023-2028)
  • Table 173. Italy Acute Intermittent Porphyria, by Diagnosis USD Million (2023-2028)
  • Table 174. Italy Acute Intermittent Porphyria, by End User USD Million (2023-2028)
  • Table 175. United Kingdom Acute Intermittent Porphyria, by Treatment USD Million (2023-2028)
  • Table 176. United Kingdom Acute Intermittent Porphyria, by Diagnosis USD Million (2023-2028)
  • Table 177. United Kingdom Acute Intermittent Porphyria, by End User USD Million (2023-2028)
  • Table 178. Netherlands Acute Intermittent Porphyria, by Treatment USD Million (2023-2028)
  • Table 179. Netherlands Acute Intermittent Porphyria, by Diagnosis USD Million (2023-2028)
  • Table 180. Netherlands Acute Intermittent Porphyria, by End User USD Million (2023-2028)
  • Table 181. Rest of Europe Acute Intermittent Porphyria, by Treatment USD Million (2023-2028)
  • Table 182. Rest of Europe Acute Intermittent Porphyria, by Diagnosis USD Million (2023-2028)
  • Table 183. Rest of Europe Acute Intermittent Porphyria, by End User USD Million (2023-2028)
  • Table 184. MEA Acute Intermittent Porphyria, by Country USD Million (2023-2028)
  • Table 185. MEA Acute Intermittent Porphyria, by Treatment USD Million (2023-2028)
  • Table 186. MEA Acute Intermittent Porphyria, by Diagnosis USD Million (2023-2028)
  • Table 187. MEA Acute Intermittent Porphyria, by End User USD Million (2023-2028)
  • Table 188. Middle East Acute Intermittent Porphyria, by Treatment USD Million (2023-2028)
  • Table 189. Middle East Acute Intermittent Porphyria, by Diagnosis USD Million (2023-2028)
  • Table 190. Middle East Acute Intermittent Porphyria, by End User USD Million (2023-2028)
  • Table 191. Africa Acute Intermittent Porphyria, by Treatment USD Million (2023-2028)
  • Table 192. Africa Acute Intermittent Porphyria, by Diagnosis USD Million (2023-2028)
  • Table 193. Africa Acute Intermittent Porphyria, by End User USD Million (2023-2028)
  • Table 194. North America Acute Intermittent Porphyria, by Country USD Million (2023-2028)
  • Table 195. North America Acute Intermittent Porphyria, by Treatment USD Million (2023-2028)
  • Table 196. North America Acute Intermittent Porphyria, by Diagnosis USD Million (2023-2028)
  • Table 197. North America Acute Intermittent Porphyria, by End User USD Million (2023-2028)
  • Table 198. United States Acute Intermittent Porphyria, by Treatment USD Million (2023-2028)
  • Table 199. United States Acute Intermittent Porphyria, by Diagnosis USD Million (2023-2028)
  • Table 200. United States Acute Intermittent Porphyria, by End User USD Million (2023-2028)
  • Table 201. Canada Acute Intermittent Porphyria, by Treatment USD Million (2023-2028)
  • Table 202. Canada Acute Intermittent Porphyria, by Diagnosis USD Million (2023-2028)
  • Table 203. Canada Acute Intermittent Porphyria, by End User USD Million (2023-2028)
  • Table 204. Mexico Acute Intermittent Porphyria, by Treatment USD Million (2023-2028)
  • Table 205. Mexico Acute Intermittent Porphyria, by Diagnosis USD Million (2023-2028)
  • Table 206. Mexico Acute Intermittent Porphyria, by End User USD Million (2023-2028)
  • Table 207. Research Programs/Design for This Report
  • Table 208. Key Data Information from Secondary Sources
  • Table 209. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Acute Intermittent Porphyria: by Treatment USD Million (2017-2022)
  • Figure 5. Global Acute Intermittent Porphyria: by Diagnosis USD Million (2017-2022)
  • Figure 6. Global Acute Intermittent Porphyria: by End User USD Million (2017-2022)
  • Figure 7. South America Acute Intermittent Porphyria Share (%), by Country
  • Figure 8. Asia Pacific Acute Intermittent Porphyria Share (%), by Country
  • Figure 9. Europe Acute Intermittent Porphyria Share (%), by Country
  • Figure 10. MEA Acute Intermittent Porphyria Share (%), by Country
  • Figure 11. North America Acute Intermittent Porphyria Share (%), by Country
  • Figure 12. Global Acute Intermittent Porphyria share by Players 2022 (%)
  • Figure 13. Global Acute Intermittent Porphyria share by Players (Top 3) 2022(%)
  • Figure 14. Global Acute Intermittent Porphyria share by Players (Top 5) 2022(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Boston Scientific Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 17. Boston Scientific Corporation (United States) Revenue: by Geography 2022
  • Figure 18. Koninklijke Philips N.V. (Netherlands) Revenue, Net Income and Gross profit
  • Figure 19. Koninklijke Philips N.V. (Netherlands) Revenue: by Geography 2022
  • Figure 20. Siemens AG(Germany) Revenue, Net Income and Gross profit
  • Figure 21. Siemens AG(Germany) Revenue: by Geography 2022
  • Figure 22. C.R. Bard Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. C.R. Bard Inc. (United States) Revenue: by Geography 2022
  • Figure 24. 3M (United States) Revenue, Net Income and Gross profit
  • Figure 25. 3M (United States) Revenue: by Geography 2022
  • Figure 26. Danaher Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 27. Danaher Corporation (United States) Revenue: by Geography 2022
  • Figure 28. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 29. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2022
  • Figure 30. Bio-Rad Laboratories, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Bio-Rad Laboratories, Inc. (United States) Revenue: by Geography 2022
  • Figure 32. ARKRAY, Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 33. ARKRAY, Inc. (Japan) Revenue: by Geography 2022
  • Figure 34. Sysmex Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 35. Sysmex Corporation (Japan) Revenue: by Geography 2022
  • Figure 36. ACON Laboratories, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 37. ACON Laboratories, Inc. (United States) Revenue: by Geography 2022
  • Figure 38. Sonova (Switzerland) Revenue, Net Income and Gross profit
  • Figure 39. Sonova (Switzerland) Revenue: by Geography 2022
  • Figure 40. Global Acute Intermittent Porphyria: by Treatment USD Million (2023-2028)
  • Figure 41. Global Acute Intermittent Porphyria: by Diagnosis USD Million (2023-2028)
  • Figure 42. Global Acute Intermittent Porphyria: by End User USD Million (2023-2028)
  • Figure 43. South America Acute Intermittent Porphyria Share (%), by Country
  • Figure 44. Asia Pacific Acute Intermittent Porphyria Share (%), by Country
  • Figure 45. Europe Acute Intermittent Porphyria Share (%), by Country
  • Figure 46. MEA Acute Intermittent Porphyria Share (%), by Country
  • Figure 47. North America Acute Intermittent Porphyria Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Boston Scientific Corporation (United States)
  • Koninklijke Philips N.V. (Netherlands)
  • Siemens AG(Germany)
  • C.R. Bard Inc. (United States)
  • 3M (United States)
  • Danaher Corporation (United States)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Bio-Rad Laboratories, Inc. (United States)
  • ARKRAY, Inc. (Japan)
  • Sysmex Corporation (Japan)
  • ACON Laboratories, Inc. (United States)
  • Sonova (Switzerland)
Select User Access Type

Key Highlights of Report


Jul 2023 200 Pages 64 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Acute Intermittent Porphyria Quantitative research analysis
Global Acute Intermittent Porphyria Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Acute Intermittent Porphyria market are Boston Scientific Corporation (United States), Koninklijke Philips N.V. (Netherlands), Siemens AG(Germany), C.R. Bard Inc. (United States), 3M (United States), Danaher Corporation (United States), F. Hoffmann-La Roche Ltd (Switzerland), Bio-Rad Laboratories, Inc. (United States), ARKRAY, Inc. (Japan), Sysmex Corporation (Japan), ACON Laboratories, Inc. (United States) and Sonova (Switzerland), to name a few.
"Increase in the Availability of Funds" is seen as one of major influencing trends for Acute Intermittent Porphyria Market during projected period 2022-2028.

Know More About Global Acute Intermittent Porphyria Report?

Have a Query? Click Here

Other Related Reports

Neurodegenerative Diseases Comprehensive Study by Application (Alzheimer's Disease, Huntington Disease, Parkinson's Disease, Amyotrophic Lateral Sclerosis), Drug Type (N-methyl-D-aspartate Receptor, ...
$ 3450
New Generation Implants Comprehensive Study by Type (Endosteal,, Subperiosteal,, Zygomatic.), Application (Orthopedic Implants, Cardiovascular Implants, Ocular Implants, Dental Implants), Raw Materia...
$ 3500
Bartter Syndrome Treatment Comprehensive Study by Type (Medication, Therapy), Application (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Genes Types (LC12A1 Gene, KCNJ1 Gene, CLCNKB Gen...
$ 3750
Nasopharyngeal Cancer Comprehensive Study by Type (Keratinizing Squamous Cell Carcinoma, Nonkeratinizing Squamous Cell Carcinoma, Undifferentiated or Poorly Differentiated), Application (Hospitals, C...
$ 3650
Pituitary cancer Comprehensive Study by Type (Surgery, Endoscopic Transnasal Transsphenoidal Surgery, Craniotomy, Radiation Therapy, Stereotactic Radiosurgery, External beam radiation, Intensity Modu...
$ 3750
Chronic Traumatic Encephalopathy (CTE) Comprehensive Study by Type (Medical Treatment, Physical Therapy), Application (Athletes, Military Veterans, Other), End Users (Hospital & Clinic, Diagnostic Ce...
$ 3650